Drugs / Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05056402 | Sep 2021 → Dec 2025 overdue | anogenital human papillomavirus infection, cervical cancer | Xiamen University | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05056402 ↗ |
| Known as | Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) | “Subjects who aged 9-17 years old would receive 2 doses of 270μg/0.5ml Recombinant HPV nonavalent (Types 6/11/16/18/31/33/45/52/58) Vaccine(E.Coli) .” NCT05056402 ↗ |
| Modality | Vaccine | “Vaccine(E.Coli)” NCT05056402 ↗ |
| Route | Intramuscular | “Three doses administered intramuscularly at 0, 1 and 6 month.” NCT05056402 ↗ |